Pazdur's perspective

Heading into the American Society of Clinical Oncology meeting, titled "Collective Wisdom: The Future of Patient-Centered Care and Research," FDA's Richard Pazdur says what patients really want are better trials, more informative data and access to investigational drugs.

In a conversation with BioCentury, the director of the Office of Hematology and Oncology Products at FDA's Center for Drug Evaluation and Research discussed the agency's views on how clinical trials and single-patient INDs, commonly called compassionate use, could be revamped to better meet patient needs...